XML 31 R16.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 10 - Income Taxes
12 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
10.
INCOME TAXES
 
A reconciliation of the provision (recovery) of income taxes to the statutory federal income tax rate is as follows:
 
 
 
 
2016
 
 
2015
 
 
2014
 
                         
Income (Loss) Before Provision for (Recovery of) Income Taxes
  $
1,333,248
    $
(122,377
)   $
8,376
 
Statutory rate
   
34
%    
34
%    
34
%
                         
     
453,304
     
(41,608
)    
2,848
 
                         
Permanent differences
   
1,000
     
900
     
1,200
 
Research and development and other credits - net
   
(47,400
)    
(48,500
)    
(46,300
)
Valuation allowance
   
(3,681,100
)    
82,200
     
44,400
 
Other
   
(25,404
)    
7,008
     
(2,148
)
                         
Total recovery of income taxes
  $
(3,299,600
)   $
-
    $
-
 
 
Deferred tax assets (liabilities) consist of the following:
 
 
 
2016
 
 
2015
 
                 
Inventories
  $
302,600
    $
81,500
 
Bad debts
   
3,400
     
3,400
 
Accrued liabilities
   
77,700
     
70,600
 
Prepaid expense
   
(8,900
)    
(13,400
)
Depreciation and amortization
   
93,000
     
46,700
 
Research and development and other credit carryforwards
   
2,019,700
     
1,980,200
 
Net operating loss carryforward
   
1,303,000
     
1,914,300
 
Directors stock option plan
   
40,100
     
40,100
 
Acquisition costs
   
-
     
125,500
 
                 
     
3,830,600
     
4,248,900
 
Valuation allowance
   
(500,000
)    
(4,248,900
)
                 
Total
  $
3,330,600
    $
-
 
 
The Company did not incur any material impact to its financial condition or results of operations due to the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
 
Valuation Reserve

The decrease in the current year valuation reserve of
$3,748,900
is due to the expiration of
$67,800
of research and development credits and a recovery of
$3,681,000
due to the likelihood that the Company will be profitable enough to utilize the majority of the net operating loss and research and development and other credit carryforwards. The increase in the prior year valuation allowance of
$82,200
is due to additional reserves due to the losses during the past several years.

Because of the uncertainties involved with this significant estimate, it is reasonably possible that the Company’s estimate
may
change in the near term.

Net Operating Loss Carryforwards:

The Company has net operating loss and research and development and other credit carryforwards for tax purposes which expire as follows:
 
Tax Year Expires
 
NOLS
 
 
R& D
& Other
Credits
 
2018 
  $
-
    $
44,980
 
2019 
   
-
     
166,019
 
2020 
   
-
     
195,753
 
2021 
   
-
     
125,939
 
2022 
   
-
     
48,573
 
2023 
   
-
     
107,172
 
2024 
   
-
     
156,392
 
2025
   
-
     
155,394
 
2026 
   
-
     
139,885
 
2027 
   
-
     
154,991
 
2028 
   
-
     
152,732
 
2029 
   
1,587,809
     
68,676
 
2030
   
942,727
     
31,081
 
2031 
   
358,744
     
44,712
 
2032
   
622,879
     
59,085
 
2033 
   
33,807
     
111,323
 
2034 
   
186,708
     
73,198
 
2035 
   
99,688
     
76,429
 
2036 
   
-
     
107,315
 
                 
    $
3,832,362
    $
2,019,649